A comparative study of anti-atherosclerotic/anti-inflammatory effect of irbesartan and rosuvastatin in hypercholesterolemic male rabbits

  • Murooj L Majeed Department of Pharmacology and Therapeutic, Faculty of Medicine, University of Kufa, Najaf, Iraq.
  • Hind F Mahdi Department of Pharmacology and Therapeutic, Faculty of Medicine, University of Kufa, Najaf, Iraq.
  • Najah R Hadi Department of Pharmacology and Therapeutic, Faculty of Medicine, University of Kufa, Najaf, Iraq.
  • Ali M Janabi Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Kufa, Najaf, Iraq.

Abstract

Objective: To evaluate the potential protective effect of irbesartan on atherosclerotic progression using rosuvastatin as a positive control.
Methods: Twenty local domestic rabbits were randomly divided into four groups, five rabbits per each group. The first group (I), rabbits were receiving normal diet; the second group (II), rabbits were receiving 2 % cholesterol diet; the third group (III), rabbits were receiving rosuvastatin and 2% cholesterol diet and; the fourth group (IV), rabbit were receiving irbesartan and 2% cholesterol diet. Serum level of cholesterol, triglycerides, LDL, VLDL and HDL were determined after 12 weeks of the study. Serum level of high sensitive C-reactive protein, ICAM1and VCAM1 were measured after 12 weeks of the study. Total antioxidant activity was also determined. Aortic tissue sent for histopathological examination of atherosclerosis lesion.
Result: Data of this study have showed that atherogenic diet caused an increase in serum level of TC, LDL, VLDL and TG and a decrease in serum level of HDL. Treatment of rabbits with irbesartan caused substantial decrease in serum lipid profile compared with untreated rabbit receiving atherogenic diet. No significant difference was seen between irbesartan- and rosuvastatin-treated rabbits in all lipid parameters measured with the exception that the HDL level in rosuvastatin-treated rabbits was significantly higher than that of irbesartan-treated rabbits. Rabbit treated with irbesartan showed a significant decrease in the serum level of high sensitive C-reactive protein, ICAM1, VCAM1 and aortic total antioxidant capacity when compared with untreated group. No significant difference was seen between irbesartan- and rosuvastatin-treated rabbits in all these inflammatory parameters measured. Histopathological examination showed that irbesartan decreased atherogenic lesion significantly when compared with untreated rabbits.
Conclusion: Irbesartan has a potential protective effect against atherosclerosis via decreasing lipid oxidation and inflammatory mediators. In terms of lipid lowering and anti-inflammatory effects, irebsartan has similar pattern of effectiveness to rosuvastatin.
share this Article by

References

1- Aziz M, and Yadav KS: Pathogenesis of Atherosclerosis a Review. Annals of Clinical and Laboratory. 2016; 4: 2386-5180.
2- Rogerio A., Sorgi C., Sadikot R. and Carlo E. The Role of Lipids Mediators in Inflammation and Resolution. BioMed Research International. 2015; (6) :1-2.

3- J. Munro and R. cotran, the pathogenesis of atherosclerosis atherogenesis and inflammation. labrotary investigation a journal of technical method and pathology.1988; 58:249-261.
4- R. dewberry, H. C. and f. s.: Interleukin 1 receptor antagonist expression in human endothelium and atherosclerosis. Arterioscler Thromb Vasc. Biol. 2000;20: 2394-2400.
5- Mercedes S., Patricia G., Teresa Tejerina: Two angiotensin AT1 receptor antagonists, irbesartan and losartan, effects in cholesterol-fed rabbits. European Journal of Pharmacology. 442 (2002) 99–106

6- Fiorentino D. Alessandra, Cianchetti S., Celi A., Dell’Omo G. , and Pedrinelli R.: The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man. Vascular Health and Risk Managment. 2009; 5: 233–242

7- Mercedes S., Patricia G., Teresa T.: Two angiotensin AT1 receptor antagonists, irbesartan and losartan, effects in cholesterol-fed rabbits .European Journal of Pharmacology. 2002; 442: 99-106
8- Blankenberg s., Barbaux s., Tiret L: Adhesion molecules and atherosclerosis. Atherosclerosis. 2003; 170:191-23.
9- D. J. Preiss, N. Sattar. Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis. International Journal of Clinical Practice. 2007; 61(4): 697–701

10- Gumieniczek A.: effect of repaglinide on oxidative stress in tissue of dibetic rabbits. Diebetic research and clinical practice. 2005 ;68(2):89-95

11- Almeida E., Blaquer D., Michiko H., Wilson R., Núñez R.: Endothelium function, lipid peroxidation, plasmatic and tissue cholesterol evaluations in mixed dyslipidemia in rabbits treated with Rosuvastatin and atorvastatin. Clínica e InvestigaciónenArteriosclerosis.2009; 21(6): 263-267.

12- Hietanen E, Aitio A, Koivusaari U, Kilpiö J, Nevalainen T, Närhi M, Savolainen H, Vainio H: Tissue concentrations and interaction of zinc with lead toxicity in rabbits. Toxicology. 1982;25(2-3):113-27.
13- CO Oguntoye & BO Oke: A Comparison of xylazine/ketamine, diazepam/ketamine and acepromazine/ketamine anesthesia in Rabbit. Sokoto Journal of Veterinary Sciences, 2014;12 (3): 21-25.
14- Yan Zhao, Keita Fukao, Songji Zhao, Ayahisa Watanabe, Tadateru Hamada, Kazuaki Yamasaki, Yoichi Shimizu, Naoki Kubo, Naoyuki Ukon, Toru Nakano, Nagara Tamaki, and Yuji Kuge: Irbesartan Attenuates Atherosclerosis in Watanabe Heritable Hyperlipidemic Rabbits. molecular imaging.2015;14:1-8.
15- Del Fiorentino Alessandra, Silvana Cianchetti, Alessandro Celi, Giulia Dell’Omo, and Roberto Pedrinelli: The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man. Vascular Health Risk Managment. 2009; 5: 233–242.

16- Wong, A.P., Mohamed, A.L. and Niedzwiecki A. Atherosclerosis and the Cholesterol Theory: A Reappraisal. World Journal of Cardiovascular Diseases. 2016; 6, 391-409.
17- Liu T., Zhang L., Joo D., and Sun S.: NF-κB signaling in inflammation. Signal Transduction and Target Therapy. 2017; 2: 17023.
18- Munger M.: Use of Angiotensin Receptor Blockers In Cardiovascular Protection. Journal of Pharmacy and Therapeutics. 2011; 36(1): 22–40.
19- L M Biasucci, M Lombardi, M Piro, G Di Giannuario, G Liuzzo, and F Crea: Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina. Heart. 2005; 91(5): 670–671
20- Lassegue B, Clepmpus RE. NAD(P)H oxidase: specific features, expression and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;285: 277–R97
21- Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2000;20: 2175–83
22- Touyz RM, Chen X, Tabet F, et al. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res. 2002; 90:1205–13.
23- Rajagopalan S, Brook R, Mehta RH, et al. Effect of losartan in aging related endothelial impairment. Am J Cardiol. 2002;89: 562–66
24- Jung O, Marklund SL, Geiger H, et al. Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSOD-deficient mice. Circ Res. 2003; 93:622–9.
25- Touyz RM, Tabet F, Schiffrin EL. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol. 2003; 30:860–6
26- Touyz RM, Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens. 2001; 19:1245–54.

27- Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol. 2004; 122:339–52.
28- A.F. Padoveze, F. Maniero, T.V. Oliveira, T.S. Vitorio, R.D. Couto, and R.C. Maranhão1: Effect of a cholesterol-rich diet on the metabolism of the free and esterified cholesterol components of a Nano emulsion that resembles LDL in rabbits. Braz J Med Biol Res. (2009) 42: 172-178
29- Li Z, Wang L, Hu X, Zhang P, Chen Y, Liu X, Xu M, Zhang Y, Zhang M: Effect of rosuvastatin on atherosclerotic plaque stability: An intravascular ultrasound elastography study. Atherosclerosis. 2016; 248:27-35.
30- T. Zhang, B. Shao, G.A. Liu: Rosuvastatin promotes the differentiation of peripheral blood monocytes into M2 macrophages in patients with atherosclerosis by activating PPAR-γ. European Review for Medical and Pharmacological Sciences. 2017; 21: 4464-4471
31- Li Z, Wang L, Hu X, Zhang P, Chen Y, Liu X, Xu M, Zhang Y, Zhang M: Effect of rosuvastatin on atherosclerotic plaque stability: An intravascular ultrasound elastography study. Atherosclerosis. 2016; 248:27-35.
Published
2019-05-03
How to Cite
MAJEED, Murooj L et al. A comparative study of anti-atherosclerotic/anti-inflammatory effect of irbesartan and rosuvastatin in hypercholesterolemic male rabbits. Journal of Contemporary Medical Sciences, [S.l.], v. 5, n. 2, may 2019. ISSN 2413-0516. Available at: <http://www.jocms.org/index.php/jcms/article/view/578>. Date accessed: 16 june 2019.
Section
Articles